HS-276 is an orally active, potent, and highly selective TAK1 inhibitor with a Ki of 2.5 nM. It significantly inhibits multiple kinases, including TAK1, CLK2, GCK, ULK2, and MAP4K5. This compound is useful for rheumatoid arthritis (RA) research due to its ability to reduce inflammation and improve arthritis markers in models.
- Orally active and highly selective TAK1 inhibitor
- Inhibits various kinases, such as TAK1, CLK2, and GCK
- Reduces expression of TNF, IL-6, and IL-1β
- Decreases inflammation and cartilage damage in inflammatory arthritis models
- Exhibits excellent bioavailability in in vivo studies
- Suitable for rheumatoid arthritis research